Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy

Ritonavir-boosted nirmatrelvir (RBN) has been authorized recently in several countries as an orally active anti-SARS-CoV-2 treatment for patients at high risk of progressing to severe COVID-19 disease. Nirmatrelvir is the active component against the SARS-CoV-2 virus, whereas ritonavir, a potent CYP...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanounou, Maor, Caraco, Yoseph, Levy, René H., Bialer, Meir, Perucca, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325946/
https://www.ncbi.nlm.nih.gov/pubmed/35895276
http://dx.doi.org/10.1007/s40262-022-01152-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325946/
https://www.ncbi.nlm.nih.gov/pubmed/35895276
http://dx.doi.org/10.1007/s40262-022-01152-z

Ejemplares similares